Crescent Biopharma Receives FDA Clearance For Its Investigational New Drug Application For CR-002 To Treat Advanced Solid Tumors

Crescent Biopharma, Inc. (NASDAQ: CBIO) has received FDA clearance for its Investigational New Drug application for CR-002, an antibody drug-conjugate targeting PD-L1, aimed at treating advanced solid tumors. This development marks a significant step in the company's efforts to advance cancer therapies.